MedTrace Logo

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2025-09-11

No results posted yet for this study

Summary

AntiCov-220 prevents and treats before, during, and after infection with SARS-CoV-2. The composition is fractionally extracted from herbs (Ascorbic Acid, L-Arginine hydrochloride, Adenosma glutinosum extract, Eclipta prostrata extract, Phyllanthus urinaria extract, Impatiens balsamina extract, Rutin, Pregnenolone acetate, Allium sativum, Pyridoxine 5-phosphate, Cyanocobalamin), using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cell-protecting processes, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

Conditions

  • Covid19

Interventions

DRUG

AntiCov-220

The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.

DRUG

AntiCov-220 (placebo)

The daily maintenance, AntiCov-220 (placebo) dose is to take 3 times a day, 1 tablet each time.

Sponsors & Collaborators

  • Nguyen Thi Trieu, MD

    lead INDIV

Principal Investigators

  • Tran Minh Cam Tu, Dr. · Saigon Biopharma Company Limited

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-20
Primary Completion
2022-04-20
Completion
2022-04-27
FDA Drug
Yes

Countries

  • United States
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043324 on ClinicalTrials.gov